[RESEARCH BLOG] · 2026-08-08

Guardian Pharmacy Services (GRDN) Rallies on Q2 Earnings Beat and Raised Full‑Year Guidance – BUY Signal in a Bull Market Regime

By Pierre Brunelle · Founder & Research Lead

GRDNBUYBULLbuy flip

Guardian Pharmacy Services, Inc. (GRDN) closed at $43.83, a +11.05 % jump from the prior session, as of 2026‑08‑07 (Friday, US session).

Guardian Pharmacy’s latest headlines coalesce around a strong second‑quarter earnings release, an upward revision of full‑year outlook, and strategic expansion moves that have attracted institutional interest. The company reported earnings that exceeded analyst expectations, lifted its 2026 revenue guidance, and announced the acquisition of a Virginia‑based long‑term‑care pharmacy network. Simultaneously, two large asset managers disclosed fresh purchases of GRDN shares, underscoring growing confidence among professional investors.

News / Catalysts

These releases collectively highlight the earnings beat, guidance upgrade, strategic acquisition, and renewed institutional appetite that are driving the stock’s recent momentum.

Fundamentals and Valuation

Guardian Pharmacy Services trades at a price‑to‑earnings (P/E) ratio of 41.74 on a trailing‑twelve‑month (TTM) basis, while the forward P/E contracts to 36.52 based on the raised FY 2026 earnings outlook. These multiples sit above the broader healthcare services average (approximately 28‑30), reflecting the market’s premium on GRDN’s growth trajectory and its niche positioning within LTCF pharmacy services.

The company’s enterprise value‑to‑EBITDA (EV/EBITDA) stands at 23.62, and EV/EBIT is 29.35, both indicating a valuation that is still elevated relative to peers that typically range between 12‑18. However, the price‑to‑book (P/B) ratio of 10.77 and price‑to‑free‑cash‑flow (P/FCF) of 34.34 suggest that investors are pricing in the expected cash‑flow uplift from recent acquisitions and the rollout of technology‑driven medication‑management tools.

Margins have shown modest improvement. Gross margin is 21.63 %, operating margin 6.27 %, and net margin 4.50 % for the most recent quarter, up from 3.40 % net margin a year earlier. The incremental margin expansion is driven by scale efficiencies and a higher proportion of higher‑margin clinical services, such as medication therapy management, which now represent roughly 12 % of total billings.

Return metrics are robust. Return on invested capital (ROIC) is 36.35 %, while return on equity (ROE) sits at 30.86 % and return on assets (ROA) at 14.86 %. These figures outpace the industry averages (ROIC ~15‑20 %) and underscore the company’s ability to generate earnings from its capital base. The Altman Z‑score of 13.53 places GRDN well within the “safe” zone, indicating low bankruptcy risk.

Growth remains a key driver. Revenue growth for the quarter was 10.31 % year‑over‑year, and EPS growth accelerated to 39 %, reflecting both higher pricing power and operational leverage. The PEG ratio of 4.68 signals that the stock’s price is still expensive relative to its earnings growth, a cautionary note for value‑oriented investors but less concerning for growth‑focused participants given the company’s strong pipeline of facility contracts.

Free‑cash‑flow yield is 2.91 %, while the buyback yield is 2.18 %, indicating that the firm is returning modest cash to shareholders while still preserving capital for strategic acquisitions. The interest coverage ratio of 145.4 highlights a very comfortable debt‑service position, despite a debt‑to‑equity (D/E) ratio of 2.86, which reflects the capital‑intensive nature of pharmacy distribution networks.

Analyst sentiment is broadly positive. The consensus target price is $45.33, implying a modest upside of roughly 3 % from the current price, while the average recommendation is “Buy.” The market’s premium appears justified by the company’s high‑quality earnings, strong cash generation, and the strategic expansion underway.

Valuation Snapshot

MetricValue
P/E (TTM)41.74
P/E (Forward)36.52
EV/EBITDA23.62
Gross Margin21.63 %
Operating Margin6.27 %
Net Margin4.50 %
ROIC36.35 %
ROE30.86 %
ROA14.86 %
PEG4.68
Interest Coverage145.4
Analyst Target Price$45.33

The historical fundamentals reinforce the narrative of a turnaround from a challenging 2024 fiscal year, when GRDN posted a negative EPS of –$1.77 and a net margin of –7.11 %. Since then, revenue has risen from $735.96 million in 2020 to $1.45 billion in 2025, a compound annual growth rate (CAGR) of roughly 9 %. EPS, after a dip in 2024, rebounded to $0.79 in 2025, and free‑cash‑flow generation has more than doubled from $44.3 million in 2020 to $80.7 million in 2025. The improvement in profitability ratios—ROE climbing from 51.83 % in 2020 to 23.92 % in 2025—reflects disciplined cost management and the benefits of scale.

ETF Ownership

Guardian Pharmacy Services is held by a modest but strategically relevant set of exchange‑traded funds. The largest holder is SAWS with a 2.91 % weighting, followed by XHS at 1.59 %, FDHT at 1.11 %, and PTH at 0.81 %. While none of these positions dominate the float, the collective exposure—approximately 6.4 % of outstanding shares—provides a layer of liquidity and can act as a stabilizing force during periods of heightened volatility.

ETFWeight
SAWS2.91 %
XHS1.59 %
FDHT1.11 %
PTH0.81 %

Concentrated institutional ownership, even at modest levels, can be a double‑edged sword. On one hand, it signals that professional managers view GRDN as a credible growth story within the healthcare services niche. On the other, any abrupt reallocation by these funds could exert pressure on the share price. For long‑term investors, the presence of these ETFs adds an element of credibility while still leaving ample room for retail participation.

LOPJLB Signal Read

The LOPJLB analytics engine flags GRDN with a BUY directional signal and a Score of 5, the highest tier in the system. The underlying market regime is classified as BULL, indicating that broader market momentum is supportive of equity‑price appreciation. Composite performance (PERF) stands at 78.10, while the quality‑focused FUND score is 60.02, placing the stock in the upper‑mid range for overall robustness.

The stock’s Value score of 46.00, Growth score of 58.00, GARP score of 27.20, and Quality score of 60.02 combine to produce a Balanced archetype. This suggests that GRDN offers a blend of growth potential, reasonable valuation relative to its earnings trajectory, and solid quality fundamentals. The LOPJLB methodology, which blends price‑action overlays, breadth indicators, and multi‑factor scoring, underpins the BUY signal.

Readers are encouraged to explore the interactive chart above on the GRDN blog page for a visual representation of the technical overlays that contributed to the signal. For a deeper dive into the scoring methodology, visit the LOPJLB methodology page.

Explore more:

The information provided herein is for research purposes only and does not constitute investment advice. All readers should conduct their own due diligence and consult professional advisors before making any investment decisions.

This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.

Open GRDN signal detail → · Open screener → · Methodology